

NOTICE TO THE BAR

CIVIL CASE INFORMATION STATEMENT (CIVIL CIS) -- PAGE 1: ADDITION OF COVID-19 INDICATOR; PAGE 4: UPDATES TO TRACK IV CASE TYPES (MULTICOUNTY LITIGATION); AND TECHNICAL REVISIONS

This notice promulgates a number of revisions to the Civil Case Information Statement (“Civil CIS”), which is included in the Rules of Court as Appendix XII-B1. The attached version of the Civil CIS reflecting those revisions will be effective May 1, 2022.

The Supreme Court has approved the addition of a COVID-19 indicator on Page 1 of the Civil CIS, specifically a question asking whether the claim is related to COVID-19.


In addition, a number of amendments are being made to Page 4 of the Civil CIS to reflect new Multicounty Litigation case types as authorized by the Court, as follows:

- The addition of case type 635 involving the drug Tassigna pursuant to the Court’s May 28, 2021 Order;
- The addition of case type 636 involving Strattice Hernia Mesh products pursuant to the Court’s October 12, 2021 Order;
- The addition of case type 638 involving the drug Elmiron pursuant to the Court’s December 7, 2021 Order; and
- The addition of case type 637 involving the drug Singulair pursuant to the Court’s January 4, 2022 Order.

The updated Civil CIS also reflects the removal of several case types for the following now-concluded MCL designations: Risperdal/Seroquel/Zyprexa (case type 274); Levaquin (case type 286); Reglan (case type 289); AlloDerm Regenerative Tissue Matrix (case type 295); Mirena Contraceptive Device (case type 297); and Propecia (case type 623).

A number of technical edits are also reflected in the amended Civil CIS.

Questions concerning these changes to the Civil CIS may be directed to Melissa A. Czartoryski, Chief, Civil Court Programs, Civil Practice Division, Administrative Office of the Courts, Hughes Justice Complex, P.O. Box 981, Trenton, New Jersey 08625-0981; telephone 609-815-2900 ext. 54900; e-mail address: Melissa.Czartoryski@njcourts.gov.



Glenn A. Grant
Administrative Director of the Courts

Dated: April 19, 2022



New Jersey Judiciary
Civil Practice Division

Civil Case Information Statement (CIS)

Use for initial Law Division Civil Part pleadings (not motions) under Rule 4:5-1. Pleading will be rejected for filing, under Rule 1:5-6(c), if information above the black bar is not completed, or attorney's signature is not affixed.

For Use by Clerk's Office Only

Payment type <input type="checkbox"/> check <input type="checkbox"/> charge <input type="checkbox"/> cash	Charge/Check Number	Amount \$	Overpayment \$	Batch Number
Attorney/Pro Se Name		Telephone Number		County of Venue
Firm Name (if applicable)			Docket Number (when available)	
Office Address - Street		City	State	Zip
Document Type			Jury Demand <input type="checkbox"/> Yes <input type="checkbox"/> No	
Name of Party (e.g., John Doe, Plaintiff)		Caption		
Case Type Number (See page 3 for listing) _____				
Are sexual abuse claims alleged?			<input type="checkbox"/> Yes	<input type="checkbox"/> No
Does this case involve claims related to COVID-19?			<input type="checkbox"/> Yes	<input type="checkbox"/> No
Is this a professional malpractice case? If "Yes," see N.J.S.A. 2A:53A-27 and applicable case law regarding your obligation to file an affidavit of merit.			<input type="checkbox"/> Yes	<input type="checkbox"/> No
Related Cases Pending? If "Yes," list docket numbers			<input type="checkbox"/> Yes	<input type="checkbox"/> No
Do you anticipate adding any parties (arising out of same transaction or occurrence)?			<input type="checkbox"/> Yes	<input type="checkbox"/> No
Name of defendant's primary insurance company (if known)			<input type="checkbox"/> None	<input type="checkbox"/> Unknown

The Information Provided on This Form Cannot be Introduced into Evidence.

Case Characteristics for Purposes of Determining if Case is Appropriate for Mediation

Do parties have a current, past or recurrent relationship? Yes No


If "Yes," is that relationship:

Employer/Employee Friend/Neighbor Familial Business

Other (explain) _____

Does the statute governing this case provide for payment of fees by the losing party? Yes No

Use this space to alert the court to any special case characteristics that may warrant individual management or accelerated disposition.

 Do you or your client need any disability accommodations? Yes No

If yes, please identify the requested accommodation:

Will an interpreter be needed? Yes No

If yes, for what language?

I certify that confidential personal identifiers have been redacted from documents now submitted to the court and will be redacted from all documents submitted in the future in accordance with Rule 1:38-7(b).

Attorney/Self-Represented Litigant Signature: _____

Civil Case Information Statement (CIS)

Use for initial pleadings (not motions) under *Rule 4:5-1*

CASE TYPES

(Choose one and enter number of case type in appropriate space on page 1.)

Track I - 150 days discovery

- 151 Name Change
- 175 Forfeiture
- 302 Tenancy
- 399 Real Property (other than Tenancy, Contract, Condemnation, Complex Commercial or Construction)
- 502 Book Account (debt collection matters only)
- 505 Other Insurance Claim (including declaratory judgment actions)
- 506 PIP Coverage
- 510 UM or UIM Claim (coverage issues only)
- 511 Action on Negotiable Instrument
- 512 Lemon Law
- 801 Summary Action
- 802 Open Public Records Act (summary action)
- 999 Other (briefly describe nature of action)

Track II - 300 days discovery

- 305 Construction
- 509 Employment (other than Conscientious Employees Protection Act (CEPA) or Law Against Discrimination (LAD))
- 599 Contract/Commercial Transaction
- 603N Auto Negligence – Personal Injury (non-verbal threshold)
- 603Y Auto Negligence – Personal Injury (verbal threshold)
- 605 Personal Injury
- 610 Auto Negligence – Property Damage
- 621 UM or UIM Claim (includes bodily injury)
- 699 Tort – Other

Track III - 450 days discovery

- 005 Civil Rights
- 301 Condemnation
- 602 Assault and Battery
- 604 Medical Malpractice
- 606 Product Liability
- 607 Professional Malpractice
- 608 Toxic Tort
- 609 Defamation
- 616 Whistleblower / Conscientious Employee Protection Act (CEPA) Cases
- 617 Inverse Condemnation
- 618 Law Against Discrimination (LAD) Cases

Track IV - Active Case Management by Individual Judge / 450 days discovery

- 156 Environmental/Environmental Coverage Litigation
- 303 Mt. Laurel
- 508 Complex Commercial
- 513 Complex Construction
- 514 Insurance Fraud
- 620 False Claims Act
- 701 Actions in Lieu of Prerogative Writs

Multicounty Litigation (Track IV)

- 271 Accutane/Isotretinoin
- 281 Bristol-Myers Squibb Environmental
- 282 Fosamax
- 285 Stryker Trident Hip Implants
- 291 Pelvic Mesh/Gynecare
- 292 Pelvic Mesh/Bard
- 293 DePuy ASR Hip Implant Litigation
- 296 Stryker Rejuvenate/ABG II Modular Hip Stem Components
- 299 Olmesartan Medoxomil Medications/Benicar
- 300 Talc-Based Body Powders
- 601 Asbestos
- 624 Stryker LFIT CoCr V40 Femoral Heads
- 625 Firefighter Hearing Loss Litigation
- 626 Abilify
- 627 Physiomesh Flexible Composite Mesh
- 628 Taxotere/Docetaxel
- 629 Zostavax
- 630 Proceed Mesh/Patch
- 631 Proton-Pump Inhibitors
- 632 HealthPlus Surgery Center
- 633 Prolene Hernia System Mesh
- 634 Allergan Biocell Textured Breast Implants
- 635 Tassigna
- 636 Strattice Hernia Mesh
- 637 Singulair
- 638 Elmiron

If you believe this case requires a track other than that provided above, please indicate the reason on page 1, in the space under “Case Characteristics”.

Please check off each applicable category

Putative Class Action

Title 59

Consumer Fraud